Classification of polycystic ovary syndrome into three types according to response to human corticotropin-releasing hormone

1999 ◽  
Vol 72 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Yoshihito Kondoh ◽  
Tsuguo Uemura ◽  
Masahiko Ishikawa ◽  
Natsuko Yokoi ◽  
Fumiki Hirahara
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Corticotropin Releasing Hormone ◽  
Ovary Syndrome ◽  
Releasing Hormone

Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome

1995 ◽  
Vol 63 (6) ◽  
pp. 1195-1199 ◽  
Author(s):  
Antonio Lanzone ◽  
Felice Petraglia ◽  
Anna Maria Fulghesu ◽  
Mario Ciampelli ◽  
Alessandro Caruso ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Adrenocorticotropic Hormone ◽  
Polycystic Ovary ◽  
Corticotropin Releasing Hormone ◽  
Ovary Syndrome ◽  
Releasing Hormone

Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome

1997 ◽  
Vol 67 (1) ◽  
pp. 34-39 ◽  
Author(s):  
Antonio Lanzone ◽  
Anna Maria Fulghesu ◽  
Maurizio Guido ◽  
Francesco Cucinelli ◽  
Alessandro Caruso ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Corticotropin Releasing Hormone ◽  
Ovary Syndrome ◽  
Releasing Hormone

Effect of long-term inhibition of gonadotrophin secretion by the gonadotrophin-releasing hormone agonist, buserelin, on sex steroid secretion and ovarian morphology in polycystic ovary syndrome

1990 ◽  
Vol 125 (2) ◽  
pp. 317-325 ◽  
Author(s):  
A. F. Macleod ◽  
M. J. Wheeler ◽  
P. Gordon ◽  
C. Lowy ◽  
P. H. Sönksen ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Gnrh Agonist ◽  
Polycystic Ovary ◽  
Normal Subjects ◽  
Sex Hormone Binding Globulin ◽  
Plasma Testosterone ◽  
Ovary Syndrome ◽  
Releasing Hormone ◽  
Gonadotrophin Releasing Hormone

ABSTRACT In order to investigate the effect of long-term suppression of the gonadotrophin axis in polycystic ovary syndrome, eight affected subjects were given s.c. infusions of gonadotrophin-releasing hormone (GnRH) agonist buserelin for 12 weeks. Hormone measurement and ultrasound studies were carried out weekly, from 6 weeks before to 12 weeks after administration of buserelin. An overnight dexamethasone-suppression test was carried out before and after treatment. Maximal suppression of LH to below the lower limit of that in normal subjects occurred after 6 weeks of treatment with buserelin. Plasma testosterone and androstenedione fell to normal levels during the infusion but reached pretreatment levels during the follow-up period. There was no effect of buserelin on plasma dehydroepiandrosterone sulphate or sex hormone-binding globulin. Ovarian size decreased significantly during the infusion with the disappearance of cysts in six subjects. After cessation of buserelin therapy, there was rapid and spontaneous ovulation which occurred within 3 weeks in all subjects. The results suggest that treatment with this GnRH agonist facilitates ovulation in this condition. Journal of Endocrinology (1990) 125, 317–325

Sign in / Sign up

Export Citation Format

Share Document